News Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-18 am EDT			5-day change	1st Jan Change
7,146 ^JPY	+0.65%		-3.21%	+5.12%

Mar. 29	Shionogi Completes Up to 75 Billion Yen Share Buyback	MT
Mar. 28	Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	Apr. 12	AQ
Shionogi Completes Up to 75 Billion Yen Share Buyback	Mar. 29	MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	Mar. 28	CI
Final dividend	Mar. 27	FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	Mar. 21	CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	Mar. 20	CI
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	Mar. 08	AQ
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	Mar. 07	MT
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	Mar. 06	AQ
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 06	AQ
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	Mar. 06	MT
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	Mar. 05	AQ
GSK says ViiV's cabotegravir study supports longer HIV dose interval	Mar. 05	AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	Mar. 05	MT
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 05	CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	Mar. 04	RE
GSK's new HIV drug formula could support longer dosing intervals (March 4)	Mar. 04	RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	Mar. 04	RE
Shionogi and Osaka University Establish a New Joint Research Lab on Post-COVID-19 Condition	Mar. 04	AQ
Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University	Mar. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Summary

Filters